This product is a derivative of isonicotinic acid. Its mechanism of action is unknown. It may have an inhibitory effect on peptide synthesis. The effect of this product on Mycobacterium tuberculosis depends on the drug concentration at the infected site. It only has an antibacterial effect at low concentrations and a bactericidal effect at high concentrations. It inhibits the synthesis of mycolic acid in Mycobacterium tuberculosis. This product has partial cross-resistance with ethionamide.

This product is a macrolide antibiotic with strong antibacterial effect on Gram-positive bacteria, including Staphylococcus, hemolytic Streptococcus, Pneumococcus, Diphtheria Corynebacterium, Tetanus Corynebacterium, and Anthrax Corynebacterium. It also has antibacterial effect on Gram-negative bacteria such as gonococci and pertussis Bordetella. Some erythromycin-resistant Staphylococcus aureus are still sensitive to kitasamycin, and it also has considerable activity against Leptospira, Rickettsia, and Mycoplasma.

This product is a polypeptide complex that has an inhibitory effect on Mycobacterium tuberculosis. The mechanism is not clear yet, but it may be related to the inhibition of bacterial protein synthesis. Bacteria are prone to develop drug resistance when used alone. This product has incomplete cross-resistance with kanamycin and puromycin.

Extracting pharmacological effects from the above information